Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-18

Neoadjuvant Nanomedicines for vascular Normalization

Cel

The aim of my proposal is to establish ‘Neoadjuvant Nanomedicines for vascular Normalization’ (NeoNaNo) as a novel concept for improving the efficacy of combined modality anticancer therapy. This concept is radically different from all other drug targeting approaches evaluated to date, since nanomedicines are not used to directly improve drug delivery to tumors, but to normalize the tumor vasculature, and to thereby indirectly improve drug (and oxygen) delivery. The need for such an alternative concept can be exemplified by taking the (pre-) clinical performance of nanomedicines into account: whereas in animal models, they generally improve both the efficacy and the tolerability of chemotherapeutic drugs, in patients, they often only attenuate the toxicity of the intervention, and they fail to improve the efficacy of the drug. To overcome this shortcoming, I here propose to use corticosteroid-containing nanomedicines, targeted to tumor-associated macrophages (TAM), to inhibit pro-inflammatory and pro-angiogenic signaling by TAM, and to thereby homogenize the tumor vasculature, increase tumor perfusion and reduce the interstitial fluid pressure. As a result of this, the tumor accumulation, intratumoral distribution and antitumor efficacy of subsequently administered chemotherapeutics, as well as of radiotherapy (because of enhanced oxygen delivery) can be substantially improved. To achieve these goals, liposomal, polymeric and micellar corticosteroids, several different animal models, and several different imaging agents and techniques will be used to (I) visualize and optimize nanomedicine-mediated vascular normalization; to (II) potentiate chemotherapy; and to (III) potentiate radiotherapy. These efforts will not only provide a solid basis for a completely new paradigm in nanomedicine research, but they will also result in novel, broadly applicable and clinically highly relevant combination regimens for improving the treatment of advanced solid malignancies.

Zaproszenie do składania wniosków

ERC-2012-StG_20111109
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

ERC-SG - ERC Starting Grant

Instytucja przyjmująca

UNIVERSITAETSKLINIKUM AACHEN
Wkład UE
€ 1 356 000,00
Adres
Pauwelsstrasse 30
52074 Aachen
Niemcy

Zobacz na mapie

Region
Nordrhein-Westfalen Köln Städteregion Aachen
Rodzaj działalności
Higher or Secondary Education Establishments
Kierownik naukowy
Twan Gerardus Gertrudis Maria Lammers (Dr.)
Kontakt administracyjny
Volker Legewie (Mr.)
Linki
Koszt całkowity
Brak danych

Beneficjenci (1)